MedTrace Logo

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

NCT02875093 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-03-05

No results posted yet for this study

Summary

Assessment of safety and tolerability of drug combination and determine time on treatment, Overall survival (OS) and response rate with patient disease burden, and type of disease

Conditions

Interventions

DRUG

ADI-PEG 20

Investigational Medicine

DRUG

Cytarabine

low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days

Sponsors & Collaborators

  • Polaris Group

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-20
Primary Completion
2019-07-10
Completion
2019-07-10
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02875093 on ClinicalTrials.gov